Education
About Us
Working with TipRanks
Follow Us
Surrozen (SRZN)
NASDAQ:SRZN
SRZN Stock Chart & Stats
$20.65
$0.24(1.85%)
At close: 4:00 PM EST
$20.65
$0.24(1.85%)
Day’s Range― - ―
52-Week Range$5.90 - $24.94
Previous CloseN/A
Volume12.23K
Average Volume (3M)25.24K
Market Cap
$154.29M
Enterprise Value-$6.52M
Total Cash (Recent Filing)$81.33M
Total Debt (Recent Filing)$7.08M
Price to Earnings (P/E)―
Beta-0.25
Next Earnings
Mar 19, 2026EPS Estimate
-1.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.36
Shares Outstanding8,571,421
10 Day Avg. Volume29,706
30 Day Avg. Volume25,240
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)-1.97
Price to Sales (P/S)3.95
P/FCF Ratio-2.38
Enterprise Value/Market Cap-0.04
Enterprise Value/Revenue-1.81
Enterprise Value/Gross Profit-1.81
Enterprise Value/Ebitda0.07
Forecast
1Y Price Target
$36.67Price Target Upside77.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated Mechanism Of ActionA Wnt-targeting approach that promotes retinal vascular repair and regeneration offers a fundamentally different therapeutic strategy from VEGF blockade, potentially delivering more durable restoration of retinal function.
External Validation And Commercial PotentialProof-of-concept data from a peer Wnt program provides mechanistic de-risking and external validation, supporting meaningful commercial upside if SZN-8141 or multi-target SZN-8143 demonstrate clinical efficacy in retinal diseases.
Regulatory MilestoneAdvancement toward an IND submission for SZN-8141 represents a clear near-term clinical and regulatory catalyst by enabling first-in-human studies of the Norrin-mimetic and anti-VEGF fusion candidate.
Bears Say
Surrozen News
SRZN FAQ
What was Surrozen’s price range in the past 12 months?
Surrozen lowest stock price was $5.90 and its highest was $24.94 in the past 12 months.
What is Surrozen’s market cap?
Surrozen’s market cap is $154.29M.
When is Surrozen’s upcoming earnings report date?
Surrozen’s upcoming earnings report date is Mar 19, 2026 which is in 63 days.
How were Surrozen’s earnings last quarter?
Surrozen released its earnings results on Nov 07, 2025. The company reported -$8.36 earnings per share for the quarter, missing the consensus estimate of -$1.135 by -$7.225.
Is Surrozen overvalued?
According to Wall Street analysts Surrozen’s price is currently Undervalued.
Does Surrozen pay dividends?
Surrozen does not currently pay dividends.
What is Surrozen’s EPS estimate?
Surrozen’s EPS estimate is -1.3.
How many shares outstanding does Surrozen have?
Surrozen has 8,571,421 shares outstanding.
What happened to Surrozen’s price movement after its last earnings report?
Surrozen reported an EPS of -$8.36 in its last earnings report, missing expectations of -$1.135. Following the earnings report the stock price went down -3.279%.
Which hedge fund is a major shareholder of Surrozen?
Currently, no hedge funds are holding shares in SRZN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Surrozen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.67 (77.58% Upside)
$36.67 (77.58% Upside)
Hedge Fund Trend
Decreased
By 19.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $10.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
127.85%
Trailing 12-Months
Company Description
Surrozen
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
SRZN Stock 12 Month Forecast
Average Price Target
$36.67
▲(77.58% Upside)
Technical Analysis
Opus Genetics
―
Ovid Therapeutics
―
Shattuck Labs
―
Spruce Biosciences
―
Biomea Fusion
―